Cardiovascular Target Program

About Micar Innovation

Micar Innovation is a private, pre-revenue biotech company providing AI-powered computational drug discovery services and developing its own internal pipeline. Its core technology platform integrates advanced molecular modeling, dynamics, and free energy calculations to de-risk and accelerate early-stage drug discovery, claiming to reduce the timeline for entire discovery processes to 2-8 weeks. The company targets orphan GPCRs, understudied proteins, and rare diseases, and has demonstrated its capabilities through published research on SARS-CoV-2 variants and partnerships for medicinal cosmetics development.

Therapeutic Areas

Other Hypertrophic Cardiomyopathy Drugs